Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

A functional link between the tumour suppressors ARF and p33ING1

Abstract

The ARF tumour suppressor protein plays a critical role in the activation of p53 in response to oncogenic stress. ARF can activate p53 through nucleolar sequestration of Mdm2. However, several lines of evidence indicate that this is not the only way of action of ARF, and alternative mechanisms must exist. p33ING1 is a putative tumour suppresor, which induces cell-cycle arrest and apoptosis in a p53-dependent manner. Here, we describe that ARF and p33ING1 can interact in vivo. We also show that the subcellular localization of ING1 can be modulated by ARF protein levels, causing a displacement from nuclear to nucleolar localization. Finally, the ability of p33ING1 to cause cell-cycle arrest and induction of p21CIP1, or Mdm2, is impaired in ARF-deficient primary mouse fibroblasts. Based on these observations, we propose that the interaction with p33ING1 represents a novel mechanism for the tumour suppression function of ARF.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Bertwistle D, Sugimoto M, Sherr CJ . (2004). Mol Cell Biol 24: 985–996.

  • Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ . (1995). Nature 377: 552–557.

  • Calabro V, Mansueto G, Santoro R, Gentilella A, Pollice A, Ghioni P et al. (2004). Mol Cell Biol 19: 8529–8540.

  • Campos EI, Chin MY, Kuo WH, Li G . (2004). Cell Mol Life Sci 61: 2597–2613.

  • D'Amico M, Wu K, Fu M, Rao M, Albanese C, Russell RG et al. (2004). Cancer Res 64: 4122–4130.

  • Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O et al. (2004). J Biol Chem 279: 36698–36707.

  • Deng C, Zhang P, Harper JW, Elledge SJ, Leder P . (1995). Cell 25: 675–684.

  • Feng X, Hara, Riabowol K . (2002). Trends Cell Biol 12: 532–538.

  • Goeman F, Thormeyer D, Abad M, Schmidt O, Serrano M, Palmero I et al. (2005). Mol Cell Biol 25: 422–431.

  • Gong W, Suzuki K, Russell M, Riabowol K . (2005). Int J Biochem Cell Biol 37: 1054–1065.

  • Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA et al. (2003). Cell 114: 99–111.

  • Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R et al. (2003). Mol Cell 12: 1151–1164.

  • Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM et al. (2004). Genes Dev 18: 830–850.

  • Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ . (1998). Proc Natl Acad Sci USA 95: 8292–8297.

  • Korgaonkar C, Zhao L, Modestou M, Quelle DE . (2002). Mol Cell Biol 22: 196–206.

  • Kuo ML, Duncavage EJ, Mathew R, den Besten W, Pei D, Naeve D et al. (2003). Cancer Res 63: 1046–1053.

  • Kuzmichev A, Zhang Y, Erdjument-Bromage H, Tempst P, Reinberg D . (2002). Mol Cell Biol 22: 835–848.

  • Leung KM, Po LS, Tsang FC, Siu WY, Lau A, Ho HT et al. (2002). Cancer Res 62: 4890–4893.

  • Llanos S, Clark PA, Rowe J, Peters G . (2001). Nat Cell Biol 3: 445–452.

  • Lowe SW, Sherr CJ . (2003). Curr Opin Genet Dev 13: 77–83.

  • Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R et al. (2001). Proc Natl Acad Sci USA 98: 9671–9676.

  • Nouman GS, Anderson JJ, Lunec J, Angus B . (2003). J Clin Pathol 56: 491–496.

  • Nourani A, Doyon Y, Utley RT, Allard S, Lane WS, Cote J . (2001. Mol Cell Biol 21: 7629–7640.

  • Palmero I, Murga M, Zubiaga A, Serrano M . (2002). Oncogene 21: 2939–2947.

  • Palmero I, Pantoja C, Serrano M . (1998). Nature 395: 125–126.

  • Pantoja C, Serrano M . (1999). Oncogene 18: 4974–4982.

  • Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. (1998). Cell 92: 713–723.

  • Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR . (2004). Nature 431: 712–717.

  • Rocha S, Campbell KJ, Perkins ND . (2003). Mol Cell 12: 15–25.

  • Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND . (2005). EMBO J 24: 1157–1169.

  • Scott M, Boisvert FM, Vieyra D, Johnston RN, Bazett-Jones DP, Riabowol K . (2001a). Nucleic Acids Res 29: 2052–2058.

  • Scott M, Bonnefin P, Vieyra D, Boisvert FM, Young D, Bazett-Jones DP et al. (2001b). J Cell Sci 114: 3455–3462.

  • Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . (1997). Cell 88: 593–602.

  • Sherr CJ . (2001). Nat Rev Mol Cell Biol 2: 731–737.

  • Shimada H, Liu TL, Ochiai T, Shimizu T, Haupt Y, Hamada H et al. (2002). Oncogene 21: 1208–1216.

  • Shinoura N, Muramatsu Y, Nishimura M, Yoshida Y, Saito A, Yokoyama T et al. (1999). Cancer Res 59: 5521–5528.

  • Skowyra D, Zeremski M, Neznanov N, Li M, Choi Y, Uesugi M et al. (2001). J Biol Chem 276: 8734–8739.

  • Sugimoto M, Kuo ML, Roussel MF, Sherr CJ . (2003). Mol Cell 11: 415–424.

  • Vogelstein B, Lane D, Levine AJ . (2000). Nature 408: 307–310.

  • Vieyra D, Loewith R, Scott M, Bonnefin P, Boisvert FM, Cheema P et al. (2002). J Biol Chem 277: 29832–29839.

  • Weber JD, Jeffer JR, Rehg JE, Randle DH, Lozano G, Roussel MF et al. (2000). Genes Dev 14: 2358–2365.

  • Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D . (1999). Nat Cell Biol 1: 20–26.

  • Xin H, Yoon HG, Singh PB, Wong J, Qin J . (2004). J Biol Chem 279: 9539–9546.

  • Yarbrough WG, Bessho M, Zanation A, Bisi JE, Xiong Y . (2002). Cancer Res 62: 1171–1177.

  • Zeremski M, Hill JE, Kwek SS, Grigorian IA, Gurova KV, Garkavtsev IV et al. (1999). J Biol Chem 274: 32172–32181.

Download references

Acknowledgements

We are grateful to Charles Sherr for p19ARF-null mice, to Gigi Lozano for p53/Mdm2-null MEFs, to Gordon Peters for GFP-p14ARF constructs and to Aria Baniahmad for p33ING1 deletion constructs. This work was supported by Grants INTACT (to MS) from the EU, and by Grants SAF2005-03018 (to MS), SAF03-0244 (to CLO) and SAF2003-00801 (to IP) from the Spanish Ministry of Science and Technology.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I Palmero.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

González, L., Freije, J., Cal, S. et al. A functional link between the tumour suppressors ARF and p33ING1. Oncogene 25, 5173–5179 (2006). https://doi.org/10.1038/sj.onc.1209526

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209526

Keywords

This article is cited by

Search

Quick links